Uterine cancer treatments

A method of eliciting an immune response in a HLA-A*02+ patient who has cancer overexpressing a MSX1 polypeptide comprising the amino acid sequence of ALAPSEGVQAA (SEQ ID NO:

• 12) and presenting at its surface a peptide consisting of the amino acid sequence of SEQ ID NO:
• 12 in complex with an MHC class I molecule, said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to selectively eliminate the cancer cells, wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of the amino acid sequence of SEQ ID NO:
• 12 in complex with an MHC class I molecule in vitro, wherein the cancer is selected from the group consisting of uterine cancer, acute myelogenous leukemia (AML), breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia (CLL), colorectal carcinoma, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular cancer (HCC), Merkel cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small cell lung cancer (SCLC), and urinary bladder cancer.